EXPEDITED PUBLICATION
A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
Albert Schömig, MD*,*,
Alban Dibra, MD*,
Stephan Windecker, MD ,
Julinda Mehilli, MD*,
José Suárez de Lezo, MD ,
Christoph Kaiser, MD ,
Seung-Jung Park, MD||,
Jean-Jacque Goy, MD,
Jae-Hwan Lee, MD¶,
Emilio Di Lorenzo, MD#,
Jinjin Wu, MD*,
Peter Jüni, MD**,
Matthias E. Pfisterer, MD,
Bernhard Meier, MD and
Adnan Kastrati, MD*
* Deutsches Herzzentrum, Technische Universität, Munich, Germany
Department of Cardiology, University Hospital Bern, Bern, Switzerland
Reina Sofia Hospital, University of Córdoba, Córdoba, Spain
University of Basel, Basel, Switzerland
|| Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
¶ Cardiovascular Center in Chungnam National University Hospital, Daejeon, Korea
# A.O.R.N. "S. G. Moscati," Avellino, Italy
** Department of Social and Preventive Medicine, University Hospital Bern, Bern, Switzerland
Service of Cardiology, Clinique Cecil, Lausanne, Switzerland
Manuscript received May 31, 2007;
revised manuscript received June 15, 2007,
accepted June 26, 2007.
* Reprint requests and correspondence: Dr. Albert Schömig, Deutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Germany. (Email: aschoemig{at}dhm.mhn.de).
Objectives: Our purpose was to make a synthesis of the available evidence on the relative efficacy and safety of 2 drug-eluting stents (DES)—sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)—in patients with coronary artery disease.
Background: It is not known whether there are differences in late outcomes between the 2 most commonly used DES: SES and PES.
Methods: Sixteen randomized trials of SES versus PES with a total number of 8,695 patients were included in this meta-analysis. A full set of individual outcome data from 5,562 patients was also available. Mean follow-up period ranged from 9 to 37 months. The primary efficacy end point was the need for reintervention (target lesion revascularization). The primary safety end point was stent thrombosis. Secondary end points were death and recurrent myocardial infarction (MI).
Results: No significant heterogeneity was found across trials. Compared with PES, SES significantly reduced the risk of reintervention (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.63 to 0.87, p < 0.001) and stent thrombosis (HR 0.66; 95% CI 0.46 to 0.94, p = 0.02) without significantly impacting on the risk of death (HR 0.92; 95% CI 0.74 to 1.13, p = 0.43) or MI (HR 0.84; 95% CI 0.69 to 1.03, p = 0.10).
Conclusions: Sirolimus-eluting stents are superior to PES in terms of a significant reduction of the risk of reintervention and stent thrombosis. The risk of death was not significantly different between the 2 DES, but there was a trend toward a higher risk of MI with PES, especially after the first year from the procedure.
|
Abbreviations and Acronyms
| | CI = confidence interval | | DES = drug-eluting stent(s) | | HR = hazard ratio | | MI = myocardial infarction | | PES = paclitaxel-eluting stent(s) | | SES = sirolimus-eluting stent(s) |
|
Related Article
-
The Emperor’s New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
- Dean J. Kereiakes
J. Am. Coll. Cardiol. 2007 50: 1381-1385.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
P. O. Vandvik, A. M. Lincoff, J. M. Gore, D. D. Gutterman, F. A. Sonnenberg, P. Alonso-Coello, E. A. Akl, M. G. Lansberg, G. H. Guyatt, and F. A. Spencer
Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Chest,
February 1, 2012;
141(2_suppl):
e637S - e668S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sarno, B. Lagerqvist, O. Frobert, J. Nilsson, G. Olivecrona, E. Omerovic, N. Saleh, D. Venetzanos, and S. James
Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J.,
January 9, 2012;
(2012)
ehr479v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Kutcher
Second-Generation Everolimus-Eluting Stents: And the Beat Goes On?
J. Am. Coll. Cardiol. Intv.,
November 1, 2011;
4(11):
1216 - 1217.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Planer, P. C. Smits, D. J. Kereiakes, E. Kedhi, M. Fahy, K. Xu, P. W. Serruys, and G. W. Stone
Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes: Pooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1104 - 1115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, C. S. Barker, M. B. Leon, L. Mauri, W. Wijns, J. Fajadet, and R. Mehran
Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1119 - 1128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, R. A. Byrne, and S. Schulz
Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1129 - 1132.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, S. Massberg, and G. Ndrepepa
Is Diabetes the Achilles' Heel of Limus-Eluting Stents?
Circulation,
August 23, 2011;
124(8):
869 - 872.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. de Waha, A. Dibra, R. A. Byrne, G. Ndrepepa, J. Mehilli, M. Fusaro, K.-L. Laugwitz, S. Massberg, A. Schomig, and A. Kastrati
Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials
Circ Cardiovasc Interv,
August 1, 2011;
4(4):
371 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Raber, P. Juni, E. Nuesch, B. Kalesan, P. Wenaweser, A. Moschovitis, A. A. Khattab, M. Bahlo, M. Togni, S. Cook, et al.
Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
J. Am. Coll. Cardiol.,
May 24, 2011;
57(21):
2143 - 2151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Otsuka, S. Ishiwata, T. Inada, H. Kanno, E. Kyo, Y. Hayashi, H. Fujita, and I. Michishita
Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry
Eur. Heart J.,
April 1, 2011;
32(7):
829 - 837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ndrepepa, L. King, and A. Kastrati
More Deserved Focus on Diabetic Patients
Circ Cardiovasc Interv,
April 1, 2011;
4(2):
115 - 117.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Farooq, B. D. Gogas, and P. W. Serruys
Restenosis: Delineating the Numerous Causes of Drug-Eluting Stent Restenosis
Circ Cardiovasc Interv,
April 1, 2011;
4(2):
195 - 205.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-Y. Lee, D.-W. Park, Y.-H. Kim, S.-C. Yun, W.-J. Kim, S.-J. Kang, S.-W. Lee, C.-W. Lee, S.-W. Park, and S.-J. Park
Incidence, Predictors, Treatment, and Long-Term Prognosis of Patients With Restenosis After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease
J. Am. Coll. Cardiol.,
March 22, 2011;
57(12):
1349 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ormiston, A. Abizaid, J. Spertus, J. Fajadet, L. Mauri, J. Schofer, S. Verheye, J. Dens, L. Thuesen, C. Dubois, et al.
Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial: A Randomized, Multicenter Comparison of the NEVO Sirolimus-Eluting Coronary Stent With the TAXUS Liberte Paclitaxel-Eluting Stent in De Novo Native Coronary Artery Lesions
Circ Cardiovasc Interv,
December 1, 2010;
3(6):
556 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-W. Park, Y.-H. Kim, S.-C. Yun, S.-J. Kang, S.-W. Lee, C.-W. Lee, S.-W. Park, I.-W. Seong, J.-H. Lee, S.-J. Tahk, et al.
Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization: The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial
J. Am. Coll. Cardiol.,
October 5, 2010;
56(15):
1187 - 1195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Simsek, M. Magro, E. Boersma, Y. Onuma, S. T. Nauta, M. P. Gaspersz, W. J. van der Giessen, R. T. van Domburg, P. W. Serruys, and on behalf of the Interventional Cardiologists of t
The Unrestricted Use of Sirolimus- and Paclitaxel-Eluting Stents Results in Better Clinical Outcomes During 6-Year Follow-Up Than Bare-Metal Stents: An Analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) Registries
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
1051 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lee, G. Tarantini, J. Xhaxho, T. Yang, A. Ehdaie, R. Bhatia, E. Favaretto, and J. Tobis
Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy
J. Am. Coll. Cardiol. Intv.,
April 1, 2010;
3(4):
378 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Eisenstein, M. B. Leon, D. E. Kandzari, L. Mauri, R. Edwards, D. F. Kong, P. A. Cowper, K. J. Anstrom, and for the ENDEAVOR III Investigators
Long-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent: 3-Year Results From the ENDEAVOR III Trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1199 - 1207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Innocente, D. Mandracchia, E. Pektok, B. Nottelet, J.-C. Tille, S. de Valence, G. Faggian, A. Mazzucco, A. Kalangos, R. Gurny, et al.
Paclitaxel-Eluting Biodegradable Synthetic Vascular Prostheses: A Step Towards Reduction of Neointima Formation?
Circulation,
September 15, 2009;
120(11_suppl_1):
S37 - S45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Novack, D. Cutlip, N. Kleiman, M. Pencina, L. Mauri, C.-H. Yen, P. Berger, S. Goldberg, M. Kellett, R. Waksman, et al.
In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents: Results From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry
J. Am. Coll. Cardiol. Intv.,
August 1, 2009;
2(8):
767 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Vlaar and F. Zijlstra
Angiographic Restenosis and Clinical Recurrence After Sirolimus- and Paclitaxel-Eluting Stent Implantation
J. Am. Coll. Cardiol. Intv.,
August 1, 2009;
2(8):
776 - 778.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Herdeg, K. Gohring-Frischholz, K. K. Haase, T. Geisler, C. Zurn, U. Hartmann, J. Wohrle, T. Nusser, J. Dippon, A. E. May, et al.
Catheter-Based Delivery of Fluid Paclitaxel for Prevention of Restenosis in Native Coronary Artery Lesions After Stent Implantation
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
294 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Thiele, P. Neumann-Schniedewind, S. Jacobs, E. Boudriot, T. Walther, F. W. Mohr, G. Schuler, and V. Falk
Randomized Comparison of Minimally Invasive Direct Coronary Artery Bypass Surgery Versus Sirolimus-Eluting Stenting in Isolated Proximal Left Anterior Descending Coronary Artery Stenosis
J. Am. Coll. Cardiol.,
June 23, 2009;
53(25):
2324 - 2331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Di Lorenzo, G. De Luca, R. Sauro, A. Varricchio, M. Capasso, T. Lanzillo, F. Manganelli, C. Mariello, F. Siano, M. R. Pagliuca, et al.
The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
515 - 523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehilli, A. Kastrati, R. A. Byrne, O. Bruskina, R. Iijima, S. Schulz, J. Pache, M. Seyfarth, S. Massberg, K.-L. Laugwitz, et al.
Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease
J. Am. Coll. Cardiol.,
May 12, 2009;
53(19):
1760 - 1768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Douglas, J. M. Brennan, K. J. Anstrom, A. Sedrakyan, E. L. Eisenstein, G. Haque, D. Dai, D. F. Kong, B. Hammill, L. Curtis, et al.
Clinical Effectiveness of Coronary Stents in Elderly Persons: Results From 262,700 Medicare Patients in the American College of Cardiology-National Cardiovascular Data Registry
J. Am. Coll. Cardiol.,
May 5, 2009;
53(18):
1629 - 1641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Awata, S. Nanto, M. Uematsu, T. Morozumi, T. Watanabe, T. Onishi, O. Iida, F. Sera, H. Minamiguchi, J.-i. Kotani, et al.
Heterogeneous Arterial Healing in Patients Following Paclitaxel-Eluting Stent Implantation: Comparison With Sirolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
453 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al.
A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus: 2-Year Clinical Outcomes of the DES-DIABETES Trial
J. Am. Coll. Cardiol.,
March 3, 2009;
53(9):
812 - 813.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chiu, D. T. Ko, P. C. Austin, E. A. Cohen, J. L. Velianou, R. Goeree, G. Blackhouse, and J. V. Tu
Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients
Circ Cardiovasc Qual Outcomes,
March 1, 2009;
2(2):
96 - 107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ryan, W. Linde-Zwirble, L. Engelhart, L. Cooper, and D. J. Cohen
Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program
Circulation,
February 24, 2009;
119(7):
952 - 961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker and P. Juni
The Drug-Eluting Stent Saga
Circulation,
February 10, 2009;
119(5):
653 - 656.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
Eur. Heart J.,
January 1, 2009;
30(1):
16 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and R. T. Gerber
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
226 - 232.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Byrne and A. Kastrati
Duration of antiplatelet therapy following intracoronary stenting: are changes needed?
Eur. Heart J. Suppl.,
November 1, 2008;
10(suppl_I):
I25 - I29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Wenaweser, J. Daemen, M. Zwahlen, R. van Domburg, P. Juni, S. Vaina, G. Hellige, K. Tsuchida, C. Morger, E. Boersma, et al.
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1134 - 1140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al.
A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus
J. Am. Coll. Cardiol.,
August 26, 2008;
52(9):
727 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al.
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
Eur. Heart J.,
August 2, 2008;
29(16):
1975 - 1982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Takano, M. Yamamoto, D. Murakami, S. Inami, K. Okamatsu, K. Seimiya, T. Ohba, Y. Seino, and K. Mizuno
Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents
Circ Cardiovasc Interv,
August 1, 2008;
1(1):
20 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Galloe, L. Thuesen, H. Kelbaek, P. Thayssen, K. Rasmussen, P. R. Hansen, N. Bligaard, K. Saunamaki, A. Junker, J. Aaroe, et al.
Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
JAMA,
January 30, 2008;
299(4):
409 - 416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mukherjee and D. J. Moliterno
Effectiveness of Drug-Eluting Stents in Real-World Patients
JAMA,
January 30, 2008;
299(4):
454 - 455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Sirolimus-Eluting vs. Paclitaxel-Eluting Stents: A Meta-Analysis
Journal Watch Cardiology,
October 3, 2007;
2007(1003):
3 - 3.
[Full Text]
|
|
|
|
|
|
|
D. J. Kereiakes
The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1381 - 1385.
[Full Text]
[PDF]
|
|
|
|
